|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, September 22, 2011 ) Belize City, Belize -- It is tough enough these days of credit tightening to get funding EAPH just announce that they have not 1 but 2 option for funding - now that huge!
No wonder this sparked a massive rally in EAPH pushing the price into double digit and up close to 240% since xtremepicks.com's alert just over a week ago.
EAPH is not done yet! Technicals are set up perfectly for a monster bullish rally – check out this solid Video Chart by Stockgoodies.com – It says it all!
http://www.youtube.com/watch?v=qmVwA_plu1U
With funding just announced, expect more monster news on distribution, patent updates, and contracts that can really push EAPH to record highs
43% of Women need ViorraTM and EAPH inches away from distribution and tapping into a “a multi-billion dollar market!”
EAPH closed at $0.103 up 29.25% on 1.6 Million shares traded – DEGH quickly jumped several times when this same level was breached!
With EAPH releasing monster PRs after another and a research report to be issued by http://www.directglobalmedia.com this weekend - itÂ’s anyones guess where this is headed toÂ…and why not have a chance to WIN $1,000 by guessing correctly!
Predict the closing price of EAPH as of September 30, 2011 and WIN $1,000 CASH Giveaway
Early bird special closes this Friday – Get your entries in soon!
ENTER THE CONTEST AT http://www.xtremepicks.com/eaph-1000-cash-giveaway-enter-now
Put some cold hard cash in your hands and keep following EAPH to guess September 30thÂ’s correct closing price and WIN BIG!
Enter now!
$2 BILLION Dollar Market for ViorraTM
Easton Pharmaceuticals is targeting the estimated $2 billion market for FSAD. Easton is also developing a pipeline of transdermal products using its proprietary technology
in Viorra for the estimated $2 billion male sexual dysfunction market, plus a variety of topical applications, including treatments for women and men seeking to diminish scars, adhesions, cellulite, varicose veins and stretch marks.
You can also keep up-to-date with Easton Pharmaceuticals product ViorraTM at http://emergingwomenshealthsolutions.com/index.html
Easton Pharmaceuticals Announces Receiving Two Financing Proposals
Easton Pharmaceuticals, a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products announced it has received and entered into discussions for two financing proposals from 2 private investment firms and accredited investors.
Easton has entered into discussions and reviewing 2 possible options available for financing. The first proposal and option presented after meetings is a conditional offer from a private investment firm and accredited investor under the condition the company first initiate the process to become a reporting issuer with the Securities and Exchange Commission. The potential investor is classified as an accredited investor based in NY State who has financed numerous public companies over the last several years. The financing is conditional and involves filing a form 10 or other type of registration statement with the SEC which entails undertaking a complete audit of its financials. Presently the company is classified as a current issuer with the OTC exchange (OTC:EAPH). The difference with being a current issuer under the present exchange is that the company presently uses a securities attorney to certify and sign off on its corporate year end and quarterly financial statements. Should the company file a form 10 and become a reporting issuer under SEC jurisdiction it would have its financial statements certified and signed off by an auditor instead of a securities attorney.
The second proposal and option presented is again from a private investment firm focused on investing in small and mid capitalized companies who is willing to finance the company via a 504 Reg D offering. Such a financing will involve the filing of a form D with the Securities and Exchange Commission with various conditions that both the company and investor must meet including investment intent by the investor. Under this option the company can raise a maximum of $1 million for every 12 month period and can be canceled at any time with no penalties or obligations.
The company is presently giving serious consideration to both proposals and options with its consultants and attorney as well as options by other firms. The 504 option is considered a quicker form of financing, but not necessarily considered a better option as only companies considered non reporting with the SEC can accept a 504 type financing and is limited to the $1 million dollar amount per 12 month period. Financing is required by the company to fulfill its corporate objectives and business plan which includes being able to market its main flagship product Viorra in various parts of the world as well as to initiate and enter into clinical North American Trials. Funding is also required for the filing of patents where the company previously advanced a retainer to a NY patent firm. Neither of the options is a guarantee that the Company will be able to close on any terms acceptable to the company but believes both are considered very good and credible. Additional details to be disclosed as they become available
ABOUT EAPH – EASTON PHARMACEUTICALS
Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops and markets a range of premium, topically delivered therapeutic health care products. The companyÂ’s proprietary gel formulation is an innovative and unique transdermal delivery system.
The system is the technology that allows for the rapid development of non-invasive, naturally derived topical solutions that have the ability to revitalize and stimulate the healing of a variety of skin and tissue conditions. The transdermal delivery system allows for the targeted delivery of active ingredients, vitamins and herbs through the skin to the underlying tissue.
The company has utilized its transdermal delivery system to develop a safe and effective female sexual enhancement product. The companyÂ’s goal is to develop a portfolio of topical pharmaceutical and cosmeceutical products targeting various skin and tissue conditions including: scars and stretch marks, cellulite and varicose veins.
Xtremepicks.com your trading connection and remember to always do your own research, use stop loss orders to protect yourself, and book your profits when in a position to do so.
Xtremepicks.com profiles are not a solicitation or recommendation to buy, sell or hold securities and is not offering securities for sale. Verify all claims and do your own due diligence. Xtremepicks receive $20K for a 2 week profile of EAPH from Direct Global Media and at times may buy EAPH in the open market. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. Click here to view the full disclaimer
Directglobalmedia.com
Max Gordon
6479227508
contact@directglobalmedia.com 
Source: EmailWire.com
|
|
|
|
